- Home
- SPAI vs CING Comparison
SPAI vs CING Comparison
Compare SPAI & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPAI | CING |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | 15 | 14 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 64.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SPAI | CING |
|---|---|---|
| Price | $4.55 | $5.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $10.00 | ★ $34.50 |
| AVG Volume (30 Days) | 73.3K | ★ 168.9K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,060.58 | N/A |
| Revenue Next Year | $162.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.23 | $3.16 |
| 52 Week High | $9.16 | $11.89 |
Technical Indicators
Market Signals| Indicator | SPAI | CING |
|---|---|---|
| Relative Strength Index (RSI) | 58.93 | 57.73 |
| Support Level | $3.57 | $4.80 |
| Resistance Level | $4.74 | $5.15 |
| Average True Range (ATR) | 0.29 | 0.28 |
| MACD | 0.11 | 0.05 |
| Stochastic Oscillator | 74.31 | 94.15 |
Price Performance
Historical ComparisonAbout SPAI Safe Pro Group Inc.
Safe Pro Group Inc operates to acquire security and protection products. The company operated in three reportable business segments, which consisted of the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. The majority of revenue is from Safe-Pro USA.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.